Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of High-Titer Anti-SARS-CoV-2 (COVID19) Convalescent Plasma for Hospitalized Patients With Infection Due to COVID-19 to Decrease Complications: A Phase II Trial

NCT04374565 is registered in ClinicalTrials.gov with University of Virginia as lead sponsor.

NCT NCT04374565
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04374565 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of High-Titer Anti-SARS-CoV-2 (COVID19) Convalescent Plasma for Hospitalized Patients With Infection Due to COVID-19 to Decrease Complications: A Phase II Trial
Lead sponsor
University of Virginia
Phase
Phase 2
Overall status
Completed
Start date
May 5, 2020
Completion date
March 5, 2021
Enrollment
29 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

corona virus infection, pneumonia, sars pneumonia, sars-cov 2